04.11.2021 • News

Nouryon Expands US Levasil Capacity

Nouryon has announced plans to expand capacity for its Levasil colloidal silica at its site in Green Bay, Wisconsin, USA. The expansion will meet rising demand from North America’s construction and packaging sectors. Construction on the facilityis expected to be completed in the second half of 2022.

Patrick Wilhelm, vice president of inorganic specialties, said large governmental infrastructure projects are fueling the demand growth in construction while e-commerce is driving higher demand for packaging materials.

In construction applications, Levasil products provide durability to structures such as bridges and buildings. They are also used to create anti-slip surfaces in packaging applications, making stacking and handling of finished products easier and more efficient.

Nouryon has eight Levasil production plants around the world. It said expansions were ongoing in Sweden and Taiwan, but did not provide further details.

Author: Elaine Burridge, Freelance Journalist

Nouryon has announced plans to expand capacity for its Levasil colloidal silica...
Nouryon has announced plans to expand capacity for its Levasil colloidal silica at its site in Green Bay, Wisconsin, USA. The expansion will meet rising demand from North America’s construction and packaging sectors. Construction should be completed in H2 2022. (c) Nouryon

Company

Logo:

Nouryon

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read